AG˹ٷ

STOCK TITAN

[8-K] Larimar Therapeutics, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Q1 FY25 (Apr–Jun 2025, J-GAAP) snapshot:

  • Ordinary income ¥2.13 tn, �10.5 % YoY on softer trading and loan yields.
  • Ordinary profit ¥368.6 bn, +4.0 % YoY; net profit attributable to owners ¥290.5 bn, +0.4 % (EPS ¥115.90).
  • Total assets fell 1.6 % since Mar-25 to ¥278.7 tn; own-capital ratio edged up to 3.7 %.
  • NPL ratio improved to 0.73 % (�23 bp); credit-related costs a modest ¥11.4 bn.

Guidance & shareholder returns: Full-year profit target lifted 8.5 % to ¥1.02 tn (15 % YoY growth), implying FY EPS ¥407.81. Dividend outlook unchanged at ¥145/share (up ¥5 YoY) with ¥72.5 interim.

Segment colour: Retail & Business Banking and CIBC drove net business profit growth; Global Markets cooled as ETF-related gains shrank to ¥3.2 bn (vs ¥31.7 bn). Net interest income rose 30 % YoY while trading income slid 14 %.

Balance-sheet trends: Loans down ¥0.14 tn to ¥94.0 tn; deposits down ¥0.62 tn to ¥154.3 tn. Unrealised gains on securities up ¥162 bn to ¥1.37 tn, aided by equity market strength. Treasury stock grew to 14.4 m shares.

Takeaway: Upgraded guidance, better asset quality and stable dividends offset revenue pressure and a still-thin capital base, signalling cautious but improving fundamentals.

Riepilogo Q1 FY25 (Apr–Giu 2025, J-GAAP):

  • Reddito ordinario ¥2,13 tn, -10,5% su base annua a causa di rendimenti più deboli su trading e prestiti.
  • Utile ordinario ¥368,6 mld, +4,0% su base annua; utile netto attribuibile ai proprietari ¥290,5 mld, +0,4% (EPS ¥115,90).
  • Totale attivi in calo dell'1,6% da marzo 2025 a ¥278,7 tn; rapporto capitale proprio in lieve aumento al 3,7%.
  • Indice NPL migliorato a 0,73% (-23 punti base); costi correlati al credito contenuti a ¥11,4 mld.

Previsioni e distribuzione agli azionisti: Target di utile annuale rivisto al rialzo dell�8,5% a ¥1,02 tn (crescita del 15% su base annua), con EPS previsto a ¥407,81. Dividendo confermato a ¥145 per azione (incremento di ¥5 su base annua), con acconto di ¥72,5.

Performance dei segmenti: Crescita del profitto netto da Retail & Business Banking e CIBC; Global Markets in calo a causa della riduzione dei guadagni legati agli ETF a ¥3,2 mld (rispetto a ¥31,7 mld). Reddito da interessi netto aumentato del 30% su base annua, mentre il reddito da trading è sceso del 14%.

Tendenze del bilancio: Prestiti diminuiti di ¥0,14 tn a ¥94,0 tn; depositi calati di ¥0,62 tn a ¥154,3 tn. Plusvalenze non realizzate su titoli aumentate di ¥162 mld a ¥1,37 tn, grazie alla forza del mercato azionario. Azioni proprie salite a 14,4 milioni di azioni.

Conclusione: Previsioni riviste al rialzo, qualità degli attivi migliorata e dividendi stabili compensano la pressione sui ricavi e una base patrimoniale ancora sottile, indicando fondamentali cautamente in miglioramento.

Resumen Q1 FY25 (Abr–Jun 2025, J-GAAP):

  • Ingresos ordinarios ¥2,13 tn, -10,5% interanual debido a menores rendimientos en trading y préstamos.
  • Beneficio ordinario ¥368,6 mil millones, +4,0% interanual; beneficio neto atribuible a los propietarios ¥290,5 mil millones, +0,4% (EPS ¥115,90).
  • Activos totales bajaron 1,6% desde marzo 2025 a ¥278,7 tn; ratio de capital propio subió ligeramente a 3,7%.
  • Ratio de préstamos dudosos mejoró a 0,73% (-23 pb); costos relacionados con crédito modestos en ¥11,4 mil millones.

Guía y retornos a accionistas: Objetivo anual de beneficio aumentado 8,5% a ¥1,02 tn (crecimiento del 15% interanual), con EPS esperado de ¥407,81. Dividendo sin cambios en ¥145 por acción (aumento de ¥5 interanual), con dividendo intermedio de ¥72,5.

Rendimiento por segmentos: Crecimiento del beneficio neto impulsado por Retail & Business Banking y CIBC; Global Markets se enfrió debido a la reducción de ganancias relacionadas con ETF a ¥3,2 mil millones (vs ¥31,7 mil millones). Ingresos netos por intereses aumentaron 30% interanual, mientras que ingresos por trading bajaron 14%.

Tendencias del balance: Préstamos bajaron ¥0,14 tn a ¥94,0 tn; depósitos bajaron ¥0,62 tn a ¥154,3 tn. Ganancias no realizadas en valores aumentaron ¥162 mil millones a ¥1,37 tn, impulsadas por la fortaleza del mercado accionario. Acciones propias aumentaron a 14,4 millones de acciones.

DzԳܲó: Guía mejorada, mejor calidad de activos y dividendos estables compensan la presión en ingresos y una base de capital aún delgada, señalando fundamentos cautelosamente en mejora.

2025 회계연도 1분기 요약 (2025� 4월~6�, J-GAAP):

  • 영업수익 2� 1,300� �, 전년 대� -10.5%� 거래 � 대� 수익 감소 영향.
  • 영업이익 3,686� �, 전년 대� +4.0%; 지배주주순이익 2,905� �, +0.4% (주당순이� 115.90�).
  • 총자산은 2025� 3� 대� 1.6% 감소� 278� 7천억 �; 자기자본비율은 소폭 상승하여 3.7% 기록.
  • 부실채권비� 개선되어 0.73% (-23bp); 신용관� 비용은 114� 엔으� 낮은 수준 유지.

가이던� � 주주환원: 연간 이익 목표� 8.5% 상향 조정하여 1� 2,020� �(전년 대� 15% 증가)으로 설정, 연간 주당순이� 예상 407.81�. 배당 전망은 주당 145엔으� 유지(전년 대� 5� 상승), 중간배당은 72.5�.

부문별 동향: 리테� � 비즈니스 뱅킹� CIBC가 순영업이� 성장 견인; 글로벌 마켓은 ETF 관� 이익 감소� 32� 엔에 그침(전년 317� � 대�). 순이자수익은 전년 대� 30% 증가, 거래수익은 14% 감소.

대차대조표 동향: 대출은 1� 4천억 � 감소� 94� �; 예금은 6� 2천억 � 감소� 154� 3천억 �. 유가증권 미실� 이익은 1,620� � 증가� 1� 3,700� �, 주식시장 강세 덕분. 자사� 보유량은 1,440� 주로 증가.

요약: 가이던� 상향, 자산 건전� 개선, 안정적인 배당� 수익 압박� 여전� 낮은 자본 기반� 상쇄하며, 신중하지� 개선되는 펀더멘털을 시사.

Résumé T1 FY25 (Avr–Juin 2025, J-GAAP) :

  • Revenus ordinaires de 2,13 billions ¥, -10,5 % en glissement annuel en raison de la baisse des rendements sur les opérations de trading et les prêts.
  • Résultat ordinaire de 368,6 milliards ¥, +4,0 % en glissement annuel ; bénéfice net attribuable aux propriétaires de 290,5 milliards ¥, +0,4 % (BPA 115,90 ¥).
  • Actifs totaux en baisse de 1,6 % depuis mars 2025 à 278,7 billions ¥ ; ratio de fonds propres en légère hausse à 3,7 %.
  • Taux de prêts non performants amélioré à 0,73 % (-23 points de base) ; coûts liés au crédit modestes à 11,4 milliards ¥.

Prévisions et rendements aux actionnaires : Objectif de bénéfice annuel relevé de 8,5 % à 1,02 billion ¥ (croissance de 15 % en glissement annuel), avec un BPA prévu de 407,81 ¥. Dividende maintenu à 145 ¥ par action (hausse de 5 ¥ en glissement annuel) avec un acompte de 72,5 ¥.

Performance par segment : La croissance du bénéfice net a été portée par la banque de détail et d’affaires ainsi que par CIBC ; les marchés mondiaux ont ralenti avec une baisse des gains liés aux ETF à 3,2 milliards ¥ (contre 31,7 milliards ¥). Le produit net d’intérêts a augmenté de 30 % en glissement annuel tandis que les revenus de trading ont diminué de 14 %.

Tendances du bilan : Prêts en baisse de 0,14 billion ¥ à 94,0 billions ¥ ; dépôts en baisse de 0,62 billion ¥ à 154,3 billions ¥. Plus-values latentes sur titres en hausse de 162 milliards ¥ à 1,37 billion ¥, soutenues par la vigueur du marché actions. Le nombre d’actions propres a augmenté à 14,4 millions.

Conclusion : Prévisions revues à la hausse, meilleure qualité des actifs et dividendes stables compensent la pression sur les revenus et une base de capital encore mince, indiquant des fondamentaux prudents mais en amélioration.

Q1 FY25 (Apr–Jun 2025, J-GAAP) Überblick:

  • Ordentliche Erträge 2,13 Bio. ¥, -10,5 % im Jahresvergleich aufgrund schwächerer Handels- und Kreditrenditen.
  • Ordentlicher Gewinn 368,6 Mrd. ¥, +4,0 % im Jahresvergleich; den Eigentümern zurechenbarer Nettogewinn 290,5 Mrd. ¥, +0,4 % (EPS 115,90 ¥).
  • Gesamtvermögen seit März 2025 um 1,6 % auf 278,7 Bio. ¥ gesunken; Eigenkapitalquote stieg leicht auf 3,7 %.
  • Notleidensquote verbesserte sich auf 0,73 % (-23 Basispunkte); kreditbezogene Kosten mit 11,4 Mrd. ¥ gering.

Prognose & Aktionärsrenditen: Jahresgewinnziel um 8,5 % auf 1,02 Bio. ¥ erhöht (15 % Wachstum gegenüber Vorjahr), prognostiziertes Jahres-EPS 407,81 ¥. Dividendenprognose unverändert bei 145 ¥ pro Aktie (plus 5 ¥ YoY) mit 72,5 ¥ Zwischenzahlung.

Segmententwicklung: Nettogewinnwachstum getrieben von Retail & Business Banking und CIBC; Global Markets schwächelte, da ETF-bezogene Gewinne auf 3,2 Mrd. ¥ schrumpften (vs. 31,7 Mrd. ¥). Nettozinserträge stiegen um 30 % YoY, Handelsgewinne sanken um 14 %.

Bilanztrends: Kredite um 0,14 Bio. ¥ auf 94,0 Bio. ¥ gesunken; Einlagen um 0,62 Bio. ¥ auf 154,3 Bio. ¥ gefallen. Nicht realisierte Wertpapiergewinne stiegen um 162 Mrd. ¥ auf 1,37 Bio. ¥, unterstützt durch starke Aktienmärkte. Eigene Aktien stiegen auf 14,4 Mio. Stück.

Fazit: Erhöhte Prognose, bessere Vermögensqualität und stabile Dividenden gleichen Umsatzdruck und weiterhin dünne Kapitalbasis aus, was auf vorsichtig verbesserte Fundamentaldaten hinweist.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Guidance raised, credit clean-up continues; revenue softness and low capital temper outlook.

MHFG’s 8.5 % hike in FY25 net-profit guidance to ¥1.02 tn is the key positive, reflecting lower funding costs and realised equity gains. Credit metrics are encouraging: NPL ratio at 0.73 % and credit costs <¥12 bn provide headroom for shareholder returns. However, ordinary income fell double-digits and Global Markets profit dropped sharply as ETF gains normalised, highlighting earnings volatility. Own-capital ratio of 3.7 % remains well below global peers, limiting buyback flexibility. Net interest income momentum (-loan spreads wider, deposit beta contained) should partially offset weaker trading, but asset and deposit contraction suggests subdued balance-sheet growth. Overall, moderately positive with valuation support from higher dividend.

TL;DR: Asset-quality gains solid; market-risk dependence and thin capital still key risks.

Sharp drop in high-risk claims (–�254 bn) and lower NPL ratio signal effective credit risk management. Securities unrealised gains improved and hedge losses narrowed, reducing OCI volatility. Yet ordinary income decline stems largely from diminished trading revenues, underscoring exposure to market swings. Capital ratio only nudged to 3.7 %, far from Basel III leverage comfort, and treasury-share increase implies limited buffer. Rising rates could pressure JGB valuations (¥67 bn latent loss). While near-term risk appears contained, structural capital weakness warrants caution; impact classified as neutral to slightly positive.

Riepilogo Q1 FY25 (Apr–Giu 2025, J-GAAP):

  • Reddito ordinario ¥2,13 tn, -10,5% su base annua a causa di rendimenti più deboli su trading e prestiti.
  • Utile ordinario ¥368,6 mld, +4,0% su base annua; utile netto attribuibile ai proprietari ¥290,5 mld, +0,4% (EPS ¥115,90).
  • Totale attivi in calo dell'1,6% da marzo 2025 a ¥278,7 tn; rapporto capitale proprio in lieve aumento al 3,7%.
  • Indice NPL migliorato a 0,73% (-23 punti base); costi correlati al credito contenuti a ¥11,4 mld.

Previsioni e distribuzione agli azionisti: Target di utile annuale rivisto al rialzo dell�8,5% a ¥1,02 tn (crescita del 15% su base annua), con EPS previsto a ¥407,81. Dividendo confermato a ¥145 per azione (incremento di ¥5 su base annua), con acconto di ¥72,5.

Performance dei segmenti: Crescita del profitto netto da Retail & Business Banking e CIBC; Global Markets in calo a causa della riduzione dei guadagni legati agli ETF a ¥3,2 mld (rispetto a ¥31,7 mld). Reddito da interessi netto aumentato del 30% su base annua, mentre il reddito da trading è sceso del 14%.

Tendenze del bilancio: Prestiti diminuiti di ¥0,14 tn a ¥94,0 tn; depositi calati di ¥0,62 tn a ¥154,3 tn. Plusvalenze non realizzate su titoli aumentate di ¥162 mld a ¥1,37 tn, grazie alla forza del mercato azionario. Azioni proprie salite a 14,4 milioni di azioni.

Conclusione: Previsioni riviste al rialzo, qualità degli attivi migliorata e dividendi stabili compensano la pressione sui ricavi e una base patrimoniale ancora sottile, indicando fondamentali cautamente in miglioramento.

Resumen Q1 FY25 (Abr–Jun 2025, J-GAAP):

  • Ingresos ordinarios ¥2,13 tn, -10,5% interanual debido a menores rendimientos en trading y préstamos.
  • Beneficio ordinario ¥368,6 mil millones, +4,0% interanual; beneficio neto atribuible a los propietarios ¥290,5 mil millones, +0,4% (EPS ¥115,90).
  • Activos totales bajaron 1,6% desde marzo 2025 a ¥278,7 tn; ratio de capital propio subió ligeramente a 3,7%.
  • Ratio de préstamos dudosos mejoró a 0,73% (-23 pb); costos relacionados con crédito modestos en ¥11,4 mil millones.

Guía y retornos a accionistas: Objetivo anual de beneficio aumentado 8,5% a ¥1,02 tn (crecimiento del 15% interanual), con EPS esperado de ¥407,81. Dividendo sin cambios en ¥145 por acción (aumento de ¥5 interanual), con dividendo intermedio de ¥72,5.

Rendimiento por segmentos: Crecimiento del beneficio neto impulsado por Retail & Business Banking y CIBC; Global Markets se enfrió debido a la reducción de ganancias relacionadas con ETF a ¥3,2 mil millones (vs ¥31,7 mil millones). Ingresos netos por intereses aumentaron 30% interanual, mientras que ingresos por trading bajaron 14%.

Tendencias del balance: Préstamos bajaron ¥0,14 tn a ¥94,0 tn; depósitos bajaron ¥0,62 tn a ¥154,3 tn. Ganancias no realizadas en valores aumentaron ¥162 mil millones a ¥1,37 tn, impulsadas por la fortaleza del mercado accionario. Acciones propias aumentaron a 14,4 millones de acciones.

DzԳܲó: Guía mejorada, mejor calidad de activos y dividendos estables compensan la presión en ingresos y una base de capital aún delgada, señalando fundamentos cautelosamente en mejora.

2025 회계연도 1분기 요약 (2025� 4월~6�, J-GAAP):

  • 영업수익 2� 1,300� �, 전년 대� -10.5%� 거래 � 대� 수익 감소 영향.
  • 영업이익 3,686� �, 전년 대� +4.0%; 지배주주순이익 2,905� �, +0.4% (주당순이� 115.90�).
  • 총자산은 2025� 3� 대� 1.6% 감소� 278� 7천억 �; 자기자본비율은 소폭 상승하여 3.7% 기록.
  • 부실채권비� 개선되어 0.73% (-23bp); 신용관� 비용은 114� 엔으� 낮은 수준 유지.

가이던� � 주주환원: 연간 이익 목표� 8.5% 상향 조정하여 1� 2,020� �(전년 대� 15% 증가)으로 설정, 연간 주당순이� 예상 407.81�. 배당 전망은 주당 145엔으� 유지(전년 대� 5� 상승), 중간배당은 72.5�.

부문별 동향: 리테� � 비즈니스 뱅킹� CIBC가 순영업이� 성장 견인; 글로벌 마켓은 ETF 관� 이익 감소� 32� 엔에 그침(전년 317� � 대�). 순이자수익은 전년 대� 30% 증가, 거래수익은 14% 감소.

대차대조표 동향: 대출은 1� 4천억 � 감소� 94� �; 예금은 6� 2천억 � 감소� 154� 3천억 �. 유가증권 미실� 이익은 1,620� � 증가� 1� 3,700� �, 주식시장 강세 덕분. 자사� 보유량은 1,440� 주로 증가.

요약: 가이던� 상향, 자산 건전� 개선, 안정적인 배당� 수익 압박� 여전� 낮은 자본 기반� 상쇄하며, 신중하지� 개선되는 펀더멘털을 시사.

Résumé T1 FY25 (Avr–Juin 2025, J-GAAP) :

  • Revenus ordinaires de 2,13 billions ¥, -10,5 % en glissement annuel en raison de la baisse des rendements sur les opérations de trading et les prêts.
  • Résultat ordinaire de 368,6 milliards ¥, +4,0 % en glissement annuel ; bénéfice net attribuable aux propriétaires de 290,5 milliards ¥, +0,4 % (BPA 115,90 ¥).
  • Actifs totaux en baisse de 1,6 % depuis mars 2025 à 278,7 billions ¥ ; ratio de fonds propres en légère hausse à 3,7 %.
  • Taux de prêts non performants amélioré à 0,73 % (-23 points de base) ; coûts liés au crédit modestes à 11,4 milliards ¥.

Prévisions et rendements aux actionnaires : Objectif de bénéfice annuel relevé de 8,5 % à 1,02 billion ¥ (croissance de 15 % en glissement annuel), avec un BPA prévu de 407,81 ¥. Dividende maintenu à 145 ¥ par action (hausse de 5 ¥ en glissement annuel) avec un acompte de 72,5 ¥.

Performance par segment : La croissance du bénéfice net a été portée par la banque de détail et d’affaires ainsi que par CIBC ; les marchés mondiaux ont ralenti avec une baisse des gains liés aux ETF à 3,2 milliards ¥ (contre 31,7 milliards ¥). Le produit net d’intérêts a augmenté de 30 % en glissement annuel tandis que les revenus de trading ont diminué de 14 %.

Tendances du bilan : Prêts en baisse de 0,14 billion ¥ à 94,0 billions ¥ ; dépôts en baisse de 0,62 billion ¥ à 154,3 billions ¥. Plus-values latentes sur titres en hausse de 162 milliards ¥ à 1,37 billion ¥, soutenues par la vigueur du marché actions. Le nombre d’actions propres a augmenté à 14,4 millions.

Conclusion : Prévisions revues à la hausse, meilleure qualité des actifs et dividendes stables compensent la pression sur les revenus et une base de capital encore mince, indiquant des fondamentaux prudents mais en amélioration.

Q1 FY25 (Apr–Jun 2025, J-GAAP) Überblick:

  • Ordentliche Erträge 2,13 Bio. ¥, -10,5 % im Jahresvergleich aufgrund schwächerer Handels- und Kreditrenditen.
  • Ordentlicher Gewinn 368,6 Mrd. ¥, +4,0 % im Jahresvergleich; den Eigentümern zurechenbarer Nettogewinn 290,5 Mrd. ¥, +0,4 % (EPS 115,90 ¥).
  • Gesamtvermögen seit März 2025 um 1,6 % auf 278,7 Bio. ¥ gesunken; Eigenkapitalquote stieg leicht auf 3,7 %.
  • Notleidensquote verbesserte sich auf 0,73 % (-23 Basispunkte); kreditbezogene Kosten mit 11,4 Mrd. ¥ gering.

Prognose & Aktionärsrenditen: Jahresgewinnziel um 8,5 % auf 1,02 Bio. ¥ erhöht (15 % Wachstum gegenüber Vorjahr), prognostiziertes Jahres-EPS 407,81 ¥. Dividendenprognose unverändert bei 145 ¥ pro Aktie (plus 5 ¥ YoY) mit 72,5 ¥ Zwischenzahlung.

Segmententwicklung: Nettogewinnwachstum getrieben von Retail & Business Banking und CIBC; Global Markets schwächelte, da ETF-bezogene Gewinne auf 3,2 Mrd. ¥ schrumpften (vs. 31,7 Mrd. ¥). Nettozinserträge stiegen um 30 % YoY, Handelsgewinne sanken um 14 %.

Bilanztrends: Kredite um 0,14 Bio. ¥ auf 94,0 Bio. ¥ gesunken; Einlagen um 0,62 Bio. ¥ auf 154,3 Bio. ¥ gefallen. Nicht realisierte Wertpapiergewinne stiegen um 162 Mrd. ¥ auf 1,37 Bio. ¥, unterstützt durch starke Aktienmärkte. Eigene Aktien stiegen auf 14,4 Mio. Stück.

Fazit: Erhöhte Prognose, bessere Vermögensqualität und stabile Dividenden gleichen Umsatzdruck und weiterhin dünne Kapitalbasis aus, was auf vorsichtig verbesserte Fundamentaldaten hinweist.

false 0001374690 0001374690 2025-07-29 2025-07-29
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 29, 2025

 

 

Larimar Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-36510   20-3857670

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

Three Bala Plaza East, Suite 506

Bala Cynwyd, Pennsylvania

  19004
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (844) 511-9056

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange

on which registered

Common Stock, par value $0.001 per share   LRMR   Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 


Item 1.01

Entry into a Material Definitive Agreement.

On July 29, 2025, Larimar Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named therein (the “Underwriters”), relating to the issuance and sale of an aggregate of 18,750,000 shares (the “Firm Shares”) of common stock, par value $0.001 per share (the “Common Stock”), of the Company at a public offering price of $3.20 per share (the “Offering”). Pursuant to the terms of the Underwriting Agreement, the Company granted the Underwriters an option, exercisable for 30 days following the date of the Underwriting Agreement, to purchase up to an additional 2,812,500 shares of Common Stock (the “Optional Shares” and together with the Firm Shares, the “Shares”) at the same price, less the underwriting discounts and commissions, which the Underwriters exercised in full on July 30, 2025.

Giving effect to the sale of the Optional Shares, the net proceeds to the Company from the Offering, after deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $64.4 million. All of the Shares in the Offering are being sold by the Company.

Leerink Partners LLC, Guggenheim Securities, LLC, Truist Securities, Inc. and William Blair & Company, L.L.C. acted as joint bookrunning managers for the Offering. The Offering is expected to close on July 31, 2025, subject to the satisfaction of customary closing conditions.

The Offering is being made pursuant to a prospectus supplement, dated July 29, 2025 (the “Prospectus Supplement”), filed with the Securities and Exchange Commission (“Commission”) on July 30, 2025 and an accompanying base prospectus that forms a part of the Company’s Registration Statement on Form S-3 (File No. 333-279275), filed with the Commission on May 9, 2024 and declared effective by the Commission on May 24, 2024.

The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement and may be subject to limitations agreed upon by the contracting parties.

The foregoing summary of the Underwriting Agreement is qualified in its entirety by reference to the Underwriting Agreement that is filed as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference.

A copy of the legal opinion of Goodwin Procter LLP relating to the legality of the issuance and sale of the Shares in the Offering is filed as Exhibit 5.1 to this Current Report on Form 8-K.


Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

Below is a list of exhibits included with this Current Report on Form 8-K.

 

Exhibit
No.

  

Document

 1.1    Underwriting Agreement, dated July 29, 2025, by and among the Company and Leerink Partners LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named therein*
 5.1    Opinion of Goodwin Procter LLP*
23.1    Consent of Goodwin Procter LLP (included in Exhibit 5.1)*
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

*

Filed herewith


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Larimar Therapeutics, Inc.
By:  

/s/ Carole S. Ben-Maimon, M.D.

Name:   Carole S. Ben-Maimon, M.D.
Title:   President and Chief Executive Officer

Date: July 31, 2025

FAQ

Why did Mizuho Financial Group (MFG) raise its FY2025 earnings guidance?

Management cites lower credit costs, improved funding spreads and realised equity gains, lifting net-profit target to ¥1.02 tn (+8.5 %).

How did credit quality trend in Q1 FY2025 for MFG?

High-risk claims fell ¥254 bn and the NPL ratio improved to 0.73 %, reflecting stronger asset quality.

What is MFG’s updated dividend outlook?

The group maintains a forecast of ¥145 per share for FY25, up ¥5 YoY, with an interim payment of ¥72.5.

How did trading activities affect Q1 results?

Net trading income dropped 14 % YoY to ¥185.1 bn; ETF gains shrank sharply, weighing on ordinary income.

What are the key balance-sheet changes since March 2025?

Total assets fell to ¥278.7 tn (�1.6 %), loans to ¥94.0 tn (–�0.14 tn) and deposits to ¥154.3 tn (–�0.62 tn).

Is MFG’s capital position improving?

Own-capital ratio edged up to 3.7 %, but remains low compared with global peers.
Larimar Therapeutics Inc

NASDAQ:LRMR

LRMR Rankings

LRMR Latest News

LRMR Latest SEC Filings

LRMR Stock Data

226.02M
63.07M
1.72%
105%
7.98%
Biotechnology
Pharmaceutical Preparations
United States
BALA CYNWYD